$15.72
-0.33 (-2.06%)
Open$15.75
Previous Close$16.05
Day High$16.14
Day Low$15.45
52W High$15.27
52W Low$9.13
Volume—
Avg Volume185.7K
Market Cap26.77M
P/E Ratio38.48
EPS$0.33
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-15.6% upside
Current
$15.72
$15.72
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.74M | 18.13M | 17.61M |
| Net Income | 675.0K | 507.1K | 519.2K |
| Profit Margin | 3.4% | 2.8% | 3.0% |
| EBITDA | 1.03M | 911.5K | 901.4K |
| Free Cash Flow | 725.0K | 739.6K | 699.1K |
| Rev Growth | -5.2% | +2.0% | -8.0% |
| Debt/Equity | 1.19 | 0.81 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |